Tofacitinib in Recurrent GBM Patients
| Заболевание | Glioblastoma |
|---|---|
| Фаза | Фаза 3 |
| Спонсор | University of Texas Southwestern Medical Center |
| Статус | Завершено |
| Участники | 18 участн. |
| Вмешательство | Tofacitinib 10mg, Temozolomide, Lomustine |
| Дата начала | 7.10.2022 |
| Дата завершения | 18.02.2025 |
| Публикация результатов | 29.06.2026 |
Кратко
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
| Newly Diagnosed or Recurrent Off Temozolomide | 4 months |
|---|---|
| Recurrent Disease on Temozolomide | 4 months |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen